Eye Surgery

Latest Issue of OR Manager
May 2024
Home Surgery/Specialties > Eye Surgery

FDA: Class I recall of CyPass Micro-Stent Systems

Editor's Note The Food & Drug Administration (FDA) on October 24 classified Alcon Research’s recall of its CyPass Micro-Stent Systems as Class I, the most serious. The recall was initiated because of the risk of corneal endothelial cell loss with the system, which is used in conjunction with cataract surgery…

Read More

By: Judy Mathias
October 30, 2018
Share

FDA: Safety Communication on Raindrop Near Vision Inlay

Editor's Note The Food & Drug Administration (FDA) on October 23 issued a Safety Communication on the increased risk of corneal haze associated with the Raindrop Near Vision Inlay, which is surgically implanted in the cornea of one eye to improve near vision. The notice is to alert eye care…

Read More

By: Judy Mathias
October 25, 2018
Share

FDA: Promise Pharmacy recalls one lot of Prednisolone, Gatifloxacin Ophthalmic Solution

Editor's Note The Food & Drug Administration (FDA) on October 22 announced the recall by Promise Pharmacy (Palm Harbor, Florida) of one lot of Prednisolone and Gatifloxacin Ophthalmic Solution 1%/0.5% sterile, 3 mL vials (Lot Number 09042018@2, Exp 12/03/2018). The recall was issued because the product was found to have…

Read More

By: Judy Mathias
October 24, 2018
Share

Cataract surgery linked to reduced traffic crashes

Editor's Note In this study, cataract surgery was associated with a patient’s reduced subsequent risk of being in a serious traffic crash as a driver. This analysis of 559,546 patients who had cataract surgery in at least one eye found that the crash rate decreased from 2.36 to 2.14 per…

Read More

By: Judy Mathias
June 28, 2018
Share

Sponsored Message

FDA issues Safety Alert for compounded drugs containing triamcinolone, moxifloxacin

Editor's Note The Food & Drug Administration (FDA) on June 14 issued a Safety Alert for compounded drugs containing triamcinolone and moxifloxacin by Guardian Pharmacy Services (Dallas, Texas). At least 43 patients have reported adverse events after receiving eye injections of the compounded triamcinolone and moxifloxacin drug during cataract surgery.…

Read More

By: Judy Mathias
June 18, 2018
Share

AANA challenges Anthem on new anesthesia policy

Editor's Note The American Association of Nurse Anesthetists (AANA) on March 19 expressed strong opposition to the decision by insurer Anthem, Inc, that ophthalmologists assume responsibility for the administration of anesthesia and patient monitoring during cataract procedures. “Ophthalmologists are no more qualified to administer anesthesia than CRNAs are to perform…

Read More

By: Judy Mathias
March 19, 2018
Share

Sponsored Message

Cataract surgery shifting from HOPDs to ASCs

Editor's Note Most patients who had cataract surgery from 2001 to 2014 did so at ambulatory surgery centers (ASCs) compared with hospital outpatient departments (HOPDs), this study finds. In this analysis of 369,320 patients who had 531,325 cataract surgeries, the proportion performed at ASCs increased from 43.6% in 2001 to…

Read More

By: Judy Mathias
December 7, 2017
Share

Study shows large shift in cataract surgery from hospitals to ASCs

Editor's Note National data show a large shift in cataract surgeries from hospitals to less expensive ambulatory surgery centers (ASCs), where care can be delivered faster and closer to home, this study finds. From 2001 to 2014, the proportion of cataract surgeries performed at ASCs increased steadily from 43.6% to…

Read More

By: Judy Mathias
November 27, 2017
Share

FDA approves first implanted lens that can be adjusted after cataract surgery

  Editor's Note The Food and Drug Administration (FDA) on November 22 announced the approval of RxSight Inc’s (Pasadena, California) Light Adjustable Lens and Light Delivery Device. This is the first system that allows ophthalmologists to make small adjustments to the implanted lens’ power after cataract surgery to improve visual…

Read More

By: Judy Mathias
November 27, 2017
Share

FDA issues Safety Alert for intraocular TMV injections

Editor's Note The Food & Drug Administration (FDA) on October 3 issued a Safety Alert saying the agency had received an adverse event report on a patient who was diagnosed with bilateral hemorrhagic occlusive retinal vasculitis after being administered injections of a compounded triamcinolone, moxifloxacin, vancomycin (TMV) formulation in each…

Read More

By: Judy Mathias
October 5, 2017
Share

Join our community

Learn More
Video Spotlight
Live chat by BoldChat